The development of precision cancer medicine that aims at the specific inhibition of oncogenic targets boosted the success of translational cancer research over the past years. The identification of novel driver oncogenes such as mutant EGFR in lung cancer patients as well as novel therapeutic strategies dramatically changed the therapeutic concepts for the treatment of virtually all cancer types. Despite the unprecedented impact of targeted therapeutics on overall survival of selected patients, the efficacy of targeted therapeutic strategies largely remains disappointing. Inefficient inhibition of the target, primary or acquired resistance and a limited repertoire of chemically accessible targets represent the major obstacles in the field.
Our lab is interested in the molecular principles that underlie the evolution of resistance against targeted therapies and the translation of genomic, transcriptomic and proteomic analyses into actionable therapeutic strategies for the treatment of cancer patients.
Dr. Katia Garbert, scientific coordination
Dr. Johannes Brägelmann, postdoctoral researcher (EKFS Fellow)
Dr. Armin Khonsari, postdoctoral researcher
Marcel Dammert, PhD student
Alena Heimsoeth, PhD student
Jenny Ostendorp, PhD student
Hannah Tumbrink, PhD student
Stefanie Lennartz, technical assistant
Nicole Russ, technical assistant
David Ast, MD student
Fatma Parmaksiz, BSc student
We are continuously looking for talented scientists with a medical, biological or computational background as well as motivated MD students driven by the desire to make a relevant contribution to the treatment of cancer patients. A high degree of excitement is a must. We offer a great environment within the lab, intensive mentoring and multiple interactions with global leaders, both from academia and industry.